Company Overview and News

38
Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates

2018-05-11 zacks
This week Eli Lilly (LLY - Free Report) announced an all-cash deal tobuy immuno-oncology biotech, ARMO Biosciences, Inc. (ARMO - Free Report) . J&J’s (JNJ - Free Report) multiple myeloma drug Darzalex gained FDA approval for combination use in first-line setting while Roche (RHHBY - Free Report) announced a couple of regulatory/pipeline updates on its PD-L1 inhibitor, Tecentriq. AstraZeneca (AZN - Free Report) sold rights to a schizophrenia product and its PARP inhibitor, Lynparza gained marketing approval in the EU.
ARMO AZN AZN 2186

59
UPDATE 1-UK Stocks-Factors to watch on May 8

2018-05-08 reuters
May 8 (Reuters) - Britain’s FTSE futures were down 0.02 percent ahead of the cash market open on Tuesday.
APO.PRB APO.PRA RDSB RDSA WIMHY APO LLOBF RYDAF WIMHF RDS.B LLOY RDS.A LYG WMH 2186 LLPH LLPK LLPJ LLPE LLPD CNQ LLPG RYDBF LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

0
AstraZeneca sells rights for Seroquel to Luye Pharma for US$538 million - Channel NewsAsia

2018-05-08 channelnewsasia
British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for US$538 million, as part of a strategy to focus on other therapy areas.
2186

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...